Everything below concerns Backbone hydrolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four-residue sequence |
| Molar mass | About 390.35 g/mol | Free peptide, counter-ion not included |
| Appearance | White to off-white powder | Lyophilised solid from aqueous solution |
| Water solubility | Freely soluble | Short, polar peptide chain |
| Common synonyms | AEDG; epithalone | Catalogues use the names interchangeably |
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
=== Need for stoichiometric control === There are two important aspects with regard to the control of molecular weight in polymerization. In the synthesis of polymers, one is usually interested in obtaining a product of very specific molecular weight, since the properties of the polymer will usually be highly dependent on molecular weight. Molecular weights higher or lower than the desired weight are equally undesirable. Since the degree of polymerization is a function of reaction time, the desired molecular weight can be obtained by quenching the reaction at the appropriate time. However, the polymer obtained in this manner is unstable, in that it leads to changes in molecular weight because the ends of the polymer molecule contain functional groups that can react further with each other. This situation is avoided by adjusting the concentrations of the two monomers so that they are slightly nonstoichiometric. One of the reactants is present in slight excess. The polymerization then proceeds to a point at which one reactant is completely used up and all the chain ends possess the same functional group of the group that is in excess. Further polymerization is not possible, and the polymer is stable to subsequent molecular-weight changes. Another method of achieving the desired molecular weight is by addition of a small amount of monofunctional monomer, a monomer with only one functional group.
=== Pathophysiological models === Clinical professionals continue to debate the causes of spontaneous upper airway blockage. The areas of thought are divided mostly into three medical groups. Some pulmonologists and neurologists believe the risk factors to be:
Cardiovascular system: pumping and channeling blood to and from the body and lungs with heart, blood and blood vessels. Digestive system: digestion and processing food with salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestines, colon, mesentery, rectum and anus. Endocrine system: communication within the body using hormones made by endocrine glands such as the hypothalamus, pituitary gland, pineal body or pineal gland, thyroid, parathyroids and adrenals, i.e., adrenal glands. Excretory system: kidneys, ureters, bladder and urethra involved in fluid balance, electrolyte balance and excretion of urine. Lymphatic system: structures involved in the transfer of lymph between tissues and the blood stream, the lymph and the nodes and vessels that transport it including the immune system: defending against disease-causing agents with leukocytes, tonsils, adenoids, thymus and spleen. Integumentary system: skin, hair and nails of mammals. Also scales of fish, reptiles, and birds, and feathers of birds. Muscular system: movement with muscles. Nervous system: collecting, transferring and processing information with brain, spinal cord and nerves. Reproductive system: the sex organs, such as ovaries, oviducts, uterus, vulva, vagina, testicles, vasa deferentia, seminal vesicles, prostate and penis. Respiratory system: the organs used for breathing, the pharynx, larynx, trachea, bronchi, lungs and diaphragm. Skeletal system: structural support and protection with bones, cartilage, ligaments and tendons.
Sources: en.wikipedia.org
== Development and test sites == Stephanie Fitzpatrick, an American geopolitical consultant, has claimed that the Chemical Research Institute in Nukus, Soviet Uzbekistan, produced Novichok agents, and The New York Times has reported that U.S. officials said the site was the major research and testing site for Novichok agents. Small, experimental batches of the weapons may have been tested on the nearby Ustyurt Plateau. Fitzpatrick also writes that the agents may have been tested in a research centre in Krasnoarmeysk near Moscow. Precursor chemicals were made at the Pavlodar Chemical Plant in Soviet Kazakhstan, which was also thought to be the intended Novichok weapons production site, until its still-under-construction chemical warfare agent production building was demolished in 1987 in view of the forthcoming 1990 Chemical Weapons Accord and the Chemical Weapons Convention. Since its independence in 1991, Uzbekistan has been working with the government of the United States to dismantle and decontaminate the sites where the Novichok agents and other chemical weapons were tested and developed. Between 1999 and 2002 the United States Department of Defense dismantled the major research and testing site for Novichok at the Chemical Research Institute in Nukus, under a $6 million Cooperative Threat Reduction program.
== Medical uses == Fixed dose combination of flupentixol and melitracen is indicated for the treatment of anxiety, depression, asthenia, neurasthenia, masked depression, psychosomatic affections accompanied by anxiety and apathy, menopausal depressions, and dysphoria or depression in alcoholics and drug addicts. and is primarily indicated for the following medical uses:
=== August === 6 August – Tom O'Connor, journalist, author, senior citizens' advocate and local politician, president of Grey Power (2016–2018), Waimate District Councillor (since 2013) (born 1944). 8 August Judy Bailey, pianist, composer, jazz musician and educator (Sydney Conservatorium of Music), and television presenter (Play School) (born 1935). Peter Lester, sailor, sailing coach and commentator, OK dinghy world champion (1977), Admiral's Cup winner (1987, 1993) (born 1954). 10 August – Patrick Waddington, Russian linguist, literary critic and historian (Victoria University of Wellington) (born 1934). 13 August – Grant Tavinor, philosopher (Lincoln University) (born c. 1973). 15 August – John Rowan, lawyer, King's Counsel (since 1997) (born 1944). 16 August – Janet Grieve, biological oceanographer (New Zealand Oceanographic Institute, NIWA), New Zealand Association of Scientists president (1998–2000), World Association of Copepodologists president (2008–2011) (born 1940). 17 August – John Bartley, cinematographer (Lost, The X Files, The Chronicles of Riddick), Emmy Award (1996) (born 1947). 18 August Lloyd Ashby, rugby union player (Southland, national team) (born 1931). Lindsay Sparks, cricketer (Central Districts, Auckland) and rugby union player (Marlborough) (born 1944). 19 August – Tony Smith, legal scholar (University of Reading, University of Cambridge, Victoria University of Wellington) (born 1947). 21 August Evelyn Attwood, tennis player (born 1924). Keith Nelson, rugby union player (Otago, Auckland, national team) and dentist (born 1938).
Sources: en.wikipedia.org
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.
The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.
No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.
The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.